This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Veeva Systems (VEEV) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Veeva Systems' (VEEV) core Subscription business segment performs impressively in Q2.
Bruker Rides on MALDI Launches Amid Coronavirus-Led Crisis
by Zacks Equity Research
For higher specific detection of the SARS-CoV-2 virus, Bruker (BRKR) launches luoroType SARS-CoV-2 plus next-generation 6-plex PCR assay.
Phibro (PAHC) Q4 Earnings Fall Short of Estimates, Margins Up
by Zacks Equity Research
Phibro's (PAHC) core Animal Health segment was aided by the Osprey Biotechnics acquisition despite a dismal overall performance in Q4 due to pandemic-led business disruptions.
AMN Healthcare's Advanced Mobile App to Aid Travel Clinicians
by Zacks Equity Research
AMN Healthcare's (AMN) new version of AMN Passport will benefit travel clinicians.
Hologic's Acessa Health Buyout to Broaden GYN Surgical Line
by Zacks Equity Research
Hologic's (HOLX) newly-acquired product line is set to complement its market-leading MyoSure products for hysteroscopic removal of fibroids.
Align Technology (ALGN) Strong on Robust Customer Adoption
by Zacks Equity Research
Align Technology (ALGN) treats the one millionth patient from the APAC region, highlighting the Invisalign system's continued adoption.
Allscripts Enhances Healthcare Innovation With Patent Program
by Zacks Equity Research
Allscripts (MDRX) continues to advance healthcare innovation by earning five new application patents.
Here's Why You Should Hold on to DENTSPLY (XRAY) Stock Now
by Zacks Equity Research
DENTSPLY (XRAY) continues to gain traction from its solid focus on R&D leading to product innovation, which continues to be a key catalyst.
Medtronic's (MDT) Q1 Earnings Beat Estimates, Margins Fall
by Zacks Equity Research
Barring Respiratory, Gastrointestinal & Renal, Medtronic (MDT) registers dismal performance in all business segments and geographies in Q1.
Insulet (PODD) Banks on Omnipod Uptake Amid Coronavirus Woes
by Zacks Equity Research
Insulet (PODD) adds significant capacity in preparation for the Omnipod 5 launch in 2021.
Amedisys & BrightStar Ink Agreement to Expand Personal Care
by Zacks Equity Research
Amedisys (AMED) strengthens Personal Care business reach by entering into an agreement with BrightStar.
QIAGEN (QGEN) to Launch COVID-19 Antibody Test in the US
by Zacks Equity Research
QIAGEN's (QGEN) latest antibody test complements its array of COVID-19 testing solutions in an economical way to detect immune responses in people who have been exposed to the SARS-CoV-2 virus.
Here's Why You Should Invest in Fresenius Medical Stock Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction from its broad range of dialysis products and services.
Top Stock Reports for JNJ, Procter & Gamble & Thermo Fisher
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Procter & Gamble (PG) and Thermo Fisher (TMO).
Has Thermo Fisher Scientific (TMO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (TMO) Outperforming Other Medical Stocks This Year?
ASCO Recommends Myriad Genetics' Test to Treat Ovarian Cancer
by Zacks Equity Research
Myriad Genetics' (MYGN) myChoice CDx test gets included in ASCO's latest recommendations for advanced ovarian cancer patients.
Medtronic's (MDT) Evolut TAVR Label Expansion Gets FDA Nod
by Zacks Equity Research
Medtronic's (MDT) Low Risk Bicuspid Study shows bicuspid patients implanted with Evolut TAVR had low rates (1.3%) of all-cause mortality.
TeleFlex Banks on Urolift Sales Amid Coronavirus-Led Debacle
by Zacks Equity Research
The acquired business of Teleflex (TFX), NeoTract has been performing impressively lately.
Here's Why You Should Hold on to NuVasive (NUVA) Stock Now
by Zacks Equity Research
Investors are optimistic about NuVasive (NUVA) on continued momentum across several recently-launched products as well as potential in its U.S. Surgical Support business.
Thermo Fisher Unveils Suite of Hematology-Oncology Solutions
by Zacks Equity Research
The Oncomine Myeloid Assay GX is the first in a series of clinical research assays available from Thermo Fisher's (TMO) new portfolio of hematology-oncology solutions.
Veeva Systems (VEEV) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal second-quarter results are likely to reflect solid show by its segments and robust product portfolio.
Here's Why You Should Retain Cardinal Health Stock for Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment, diversified product portfolio and strategic buyouts.
Thermo Fisher (TMO) Up 2.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medtronic Initiates Post-Market ELITE Study for SNM Therapy
by Zacks Equity Research
Medtronic's (MDT) ELITE study is expected to reinforce long-term safety, efficacy and patient benefit from the SNM therapy.
MedTech Lifts S&P 500 Index: 3 Stocks With Upside Potential
by Urmimala Biswas
MedTech stocks play a major role in holding the index up and ending the shortest bear run in the history of S&P 500.